


Stabilis



Phenobarbital sodium



Noms commerciaux

Carbital	Brésil
Fenemal	Suède
Fenobarb	Inde
Fenobarbital	Argentine, Colombie, Equateur
Gardenal	Brésil, France, Grande Bretagne, Inde, Maroc, Tunisie, Vénézuéla
Luminal	Allemagne, Espagne, Iran
Luminale	Italie
Luminalum	Pologne
Phenobarbital sodium	Canada, Grande Bretagne
Sominaletta	Egypte



Stabilité des solutions

		10 mg/ml	4°C		28			349



Stabilité en mélange

		65 mg/ml	25°C		Fosphenytoin sodium : 5 mg/ml	8		1412



































Facteur influençant la stabilité

				1415
				3379



Compatibilités

			
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 5 mg/ml	 301
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 5 mg/ml Doripenem : 5 mg/ml	 2262
	<input type="checkbox"/>	Phenobarbital sodium : 64 mg/ml	 3379
	<input type="checkbox"/>	Phenobarbital sodium : 5 mg/ml	 1415
	<input type="checkbox"/>	Phenobarbital sodium : 5 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	 921
	<input type="checkbox"/>	Phenobarbital sodium Atracurium besylate	3676
	<input type="checkbox"/>	Phenobarbital sodium Chlorpromazine hydrochloride	3596
	<input type="checkbox"/>	Phenobarbital sodium Clindamycin phosphate	3526
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 10 mg/ml Doxapram hydrochloride : 2 mg/ml	 1802
	<input type="checkbox"/>	Phenobarbital sodium Droperidol	4009
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 0.32 mg/ml Enalaprilate : 1.25 mg/ml	 201
	<input type="checkbox"/>	Phenobarbital sodium Erythromycin lactobionate	3674
	<input type="checkbox"/>	Phenobarbital sodium Esketamine	4700
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 2 mg/ml Fentanyl citrate : 25 µg/ml	 1974
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 65 mg/ml Fosphenytoin sodium : 5 mg/ml	 1412
	<input type="checkbox"/>	Phenobarbital sodium : 120 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml	 226
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 2 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml	 1974
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 30 mg/ml Ibuprofen lysinate : 10 mg/ml	 4419
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 130 mg/ml Ibuprofen lysinate : 10 mg/ml	 4419
	<input type="checkbox"/>	Phenobarbital sodium Ketamine hydrochloride	3501
	<input type="checkbox"/>	Phenobarbital sodium : 5 mg/ml Lansoprazole : 0.55 mg/ml	 1625
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 130 mg/ml Levofloxacin : 5 mg/ml	 1072
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 5 mg/ml Linezolid : 2 mg/ml	 1925
	<input checked="" type="checkbox"/>	Phenobarbital sodium : 0.2 mg/ml Meropenem : 1 & 20 mg/ml	 266

	Phenobarbital sodium : 0.32 mg/ml Meropenem : 1 & 50 mg/ml		266
	Phenobarbital sodium : 2 mg/ml Methadone hydrochloride : 1 mg/ml		1974
	Phenobarbital sodium Morphine sulfate		3531
	Phenobarbital sodium : 2 mg/ml Morphine sulfate : 1 mg/ml		1974
	Phenobarbital sodium : 60 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Phenobarbital sodium Norepinephrine bitartrate		642
	Phenobarbital sodium Pantoprazole sodium		2090
	Phenobarbital sodium : 120 mg/ml Paracetamol : 10 mg/ml		4742
	Phenobarbital sodium : 100 mg/ml Paracetamol : 10 mg/ml		4435
	Phenobarbital sodium : 20 mg/ml Pentoxifyllin : 5 mg/ml		4543
	Phenobarbital sodium Pethidine hydrochloride		3525
	Phenobarbital sodium : 5 mg/ml Propofol : 10 mg/ml		300
	Phenobarbital sodium : 65 mg/ml Propofol		660
	Phenobarbital sodium : 120 mg/ml Ranitidine hydrochloride : 25 mg/ml		58
	Phenobarbital sodium Suxamethonium chloride		3631
	Phenobarbital sodium : 0.26 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057



Voie d'administration



Bibliographie

	Type	Source
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
201	Revue	Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531.


226	Revue	Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
349	Revue	Nahata MC, Hipple TF, Strausbaugh SD. Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection. Am J Hosp Pharm 1986 ; 43: 384-385.
642	Revue	Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	Revue	Saltzman CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1412	Revue	Brett A, Riggs RM, Webster AA, Benner KW. Y-site stability of fosphenytoin and sodium phenobarbital. Int J Pharm Compound 1999 ; 3: 64-66.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.

2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3501	Laboratoire	Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics Pfizer 2011
3525	Laboratoire	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3531	Laboratoire	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3596	Laboratoire	Chlorpromazine (Largactil®) - Summary of Product Characteristics Sanofi 2014
3631	Laboratoire	Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit Aguettant 2016
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3676	Laboratoire	Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit Hospira 2014
4009	Laboratoire	Droperidol - Résumé des Caractéristiques du Produit
4419	Revue	Holpari S, Datta S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4435	Revue	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4700	Laboratoire	Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics AS Kalceks 2022
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Stabilis



Phenobarbital sodium



Stabilité des préparations

		1350 mg ® = ?	SyrSpend SF PH4® >> 150 ml	2-8°C	?	90			4177
600 mg ® = ?		(Exellium Pharmaceuticals)	OraPlus® 30 ml Orasweet ® 30 ml	23-25°C		115			2401
600 mg ® = ?		(Exellium Pharmaceuticals)	OraPlus® 30 ml Orasweet SF ® 30 ml	23-25°C		115			2401
		926 mg ® = ?	SyrSpend SF PH4® >> 100 mL	25°C	?	154			3810
		898 mg ® = ?	SyrSpend SF PH4 Cherry® >> 100 mL	25°C	?	154			3810



Bibliographie

	Type	Source
2401	Revue	Cober MP, Johnson CE. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension Am J Health-Syst Pharm 2007 ; 64: 644-646.
3810	Revue	Geiger C M, Sorenson B, Whaley P. Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF. Int J Pharm Compound 2015 ; 19, 5 : 420-427.

4177	Revue	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
------	-------	---



Dictionnaire

	Antiépileptique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	Chlorure de sodium 0,9%		A l'abri de la lumière
	Jour		Stabilité en mélange
	Solvant		Molécule
	Non précisée		Heure
	Facteur influençant la stabilité		Nutrition parentérale (mélange ternaire)
	Provoque		Dégradation
	Nutrition parentérale (mélange binaire)		Compatibilités
	Compatible		NaCl 0,9% ou glucose 5%
	Précipitation immédiate		Incompatible
	Instabilité de l'émulsion immédiate		Turbidité immédiate
	Glucose 5%		Incompatibilité non précisée
	Eau pour préparation injectable		Aucun
	Précipitation en 4 heures		Voie d'administration
	Perfusion intraveineuse		Intramusculaire
	Sous cutanée		Perfusion SC continue
	Bibliographie		Anxiolytique
	Solution buvable		Stabilité des préparations
	Origine		Excipient
	Flacon plastique		Poudre
	Comprimés		Dictionnaire